Ustekinumab may trigger severe cardiovascular events in high-risk individuals

Treatment of psoriatic conditions or Crohn’s disease with ustekinumab was associated with severe cardiovascular events in certain high-risk patients, according to a study.Florence Poizeau, MD, and colleagues aimed to assess whether initiation of the interleukin-12/23p40 antibody ustekinumab would lead to severe cardiovascular events in patients with moderate to severe psoriasis, psoriatic arthritis and Crohn’s disease.The case-time-control analysis included findings for 9,290 patients culled from the French national health insurance database; all individuals were exposed toRead More

Share on facebook
Share on twitter
Share on linkedin